Investigator Studies Program (MISP): Antimicrobial Stewardship
Effective December 2020, the Antimicrobial Stewardship Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 14, 2021. This is a competitive process that will be conducted by the Antimicrobial Stewardship MISP in 2021. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.

The following areas are of interest to Investigator Studies Program Committee:
  • Evaluation of the most effective strategies for antimicrobial stewardship (AS), including surveillance, infection prevention, streamlining of antibiotic therapy in traditional and alternative settings, transitions of care, special/vulnerable populations, and/or resource limited settings
  • Integration of ASPs across integrated delivery networks (IDNs), accountable care organizations (ACOs), or ASP practices in regions with unmet need
  • Identifying risk factors/drivers for inappropriate or ineffective antimicrobial use decisions and/or variability in antimicrobial prescribing across prescribers and regions and evaluation of strategies to improve such decision making/increase consistency with evidence-based practices
  • Use of clinical decision support within electronic medical records and/or telemedicine for ASPs and the impact of those tools on patient outcome
  • Use of clinical decision support within electronic medical records and/or telemedicine for ASPs and the impact of those tools on patient outcome
  • Use of implementation and/or behavioral and/or social sciences relative to the conduct of ASPs. For example:
    • Assessment of two different ways of implementing the same intervention (e.g., using verbal conversation vs prescription pad for self-care/OTC products vs giving a cold care kit to try to reduce inappropriate outpatient prescribing), or
    • Assessment of an intervention such as “handshake stewardship”, peer benchmarking, or nudge interventions
  • Evaluation of the impact of ASP intervention(s) on outcomes that may include, but are not limited to, the following:
    • Unintended consequences of antibiotic use (e.g. toxicity, resistance, selection of pathogenic organisms, effects on microbiome)
    • novel metrics for ASPs and something related to development/validation/demonstration of surrogate measures that can be used for “more difficult-to-collect” outcomes (e.g., do process measures like appropriate therapy, guideline adherence, etc. actually correlate to improved patient outcomes?)
    • Assessment of specific AMR trends over time in an institution, healthcare system or patient and the impact of an ASP intervention on those trends
  • Effect of the COVID-19 pandemic on the conduct, modification, or impact of inpatient or outpatient ASPs.

Please complete a protocol and detailed budget via Visiontracker, the Company's on-line study management system (in US). The proposals will be collectively reviewed and selected by the Antimicrobial Stewardship MISP Committee.

Critical Activities and Timelines:
Activity 1st Review Cycle
Protocol Submission with Detailed Budget May 14, 2021
MISP-RC Review Meeting June 29, 2021

MISP Information
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator Studies Program should contact their local MSD office.